- Russia says it has successfully completed human trials of a COVID-19 vaccine
- This particular vaccine was reportedly developed by Oxford University
- The trial, according to researchers, shows promise and proves the vaccine is safe
Brazil might have been the first country to test the Covid-19 vaccine developed by Oxford University, but it appears Russia has made it to the finish line first.
The nation has successfully completed human trials of the vaccine, with Elena Smolyarchuk from the Russian Center for Clinical Research on Medications at Sechenow University, saying that test patients are set to be discharged soon:
"The research has been completed and it proved that the vaccine is safe. The volunteers will be discharged on July 15 and July 20."
Forbes reports that there is no indication as to when the vaccine will enter commercial production, but nevertheless this bodes well for the global fight against the virus.
Over 21 vaccines are currently under trial worldwide, according to the World Health Organisation.
Meanwhile, Briefly.co.za reported that clinical trials had begun in South Africa although it remains unclear if it is the same vaccine as the one that has enjoyed success in Russia.
The trial will be led by Shabir Madhi, Professor of Vaccinology at Wits University and Director of the South Africa Medical Research Council (SAMRC) Vaccines and Infectious Diseases Analytics Research Unit (VIDA).
Commenting at the launch of the vaccine trial, which will take place at numerous sites in SA, Madhi said that:
“This is a landmark moment for South Africa and Africa at this stage of the Covid-19 pandemic. As we enter winter in South Africa and pressure increases on public hospitals, now more than ever we need a vaccine to prevent infection by Covid-19."
Vox pop: Which team "Nana-Bawumia or Jane-John" will win the 2020 election? | #Yencomgh
Have national and human interest issues to discuss?
Know someone who is extremely talented and needs recognition?
Your stories and photos are always welcome. Get interactive via our Facebook page.